Kevan Shokat, Ph.D.
Simon Campbell, Ph.D.
Kapil Dhingra, M.D.
Gary S. Firestein, M.D.
David Fruman, Ph.D.
Stephen V. Frye, Ph.D.
John Gribben M.D. DSc FRCP FRCPath FMedSci
Zachary Knight, Ph.D.
David Pearce, M.D.
Neal Rosen, M.D., Ph.D.
Richard M. Soll, Ph.D.
Edgar Ulm, Ph.D.
Bart Vanhaesebroeck, MSc, Ph.D.
Kevan Shokat, Ph.D.
Chairman
Professor Shokat is a co-founder of Intellikine and serves as the Chairman of our Scientific Advisory Board. He is currently an Investigator of the Howard Hughes Medical Institute, Professor and Co-Chair of the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco and Professor of Chemistry at the University of California at Berkeley. Professor Shokat is a pioneer in the development of chemical methods for investigating cellular signal transduction pathways—with a particular focus on protein kinases and lipid kinases. His laboratory uses a combination of chemical synthesis and protein engineering to create uniquely traceable and regulatable kinases, allowing the function of more than 100 different kinases to be uncovered across all disease areas including oncology, metabolism, and infectious disease. Professor Shokat has received numerous awards for his work, including being named a Fellow of the Pew Foundation, Searle Foundation, Sloan Foundation, Glaxo-Wellcome Foundation, and the Cotrell Foundation. He has also received the Eli Lilly Award, given to the most promising biological chemist in the country under the age of 37. Professor Shokat is active in the development and commercialization of inventions made in his laboratory. He is a co-founder of Cellular Genomics, Inc., a company focused in New Haven, Connecticut, as well as a member of several other Scientific Advisory Boards including the Scientific Advisor Network of the DDS of Invitrogen Corporation and the Scientific Research Board of Genentech.
Simon Campbell, Ph.D.
Dr. Campbell joined Pfizer Central Research, Sandwich in 1972, as a medicinal chemist, and he retired from Pfizer in October 1998 as Senior Vice President for Worldwide Discovery and Medicinals R&D Europe. He has co-authored over 115 publications and patents, and was a key member of the research teams that discovered doxazosin (Cardura™) and amlodipine (Norvasc™). Both of these novel medicines became the leading agents worldwide in their therapeutic class. In addition, he was senior author on the research proposal that led to sildenafil (Viagra™), the first oral treatment for Male Erectile Dysfunction. Dr. Campbell has been recognized with numerous awards for his scientific contributions. Dr Campbell was President of the Royal Society of Chemistry (2004-06), and was awarded a CBE in the Queen's 80th Birthday Honours List (2006) "for services to science."
Kapil Dhingra, M.D.
Dr. Dhingra is a medical oncologist and a physician-scientist. He received his medical training at the All India Institute of Medical Sciences, New Delhi, India, followed by Lincoln Medical Center, New York, NY and Emory University, Atlanta, GA. In 1989, he joined the faculty of M.D. Anderson Cancer Center, Houston, Texas. Subsequently he held faculty appointments at the Indiana University School of Medicine, Indianapolis, IN (1996-1999) and Memorial Sloan Kettering Cancer Center, New York, NY (2000-2008). He has authored or co-authored more than 100 publications and abstracts. In addition to the editorial board of R&D Directions, Dr. Dhingra serves on the Editorial Board of Future Drugs and the Editorial Advisory Board of R&D Directions. Dr Dhingra joined Eli Lilly and Company in 1996. He joined Roche in 1999 and was promoted, in 2002, to Vice President, Oncology. He played a key role in the dramatic expansion of Roche oncology enterprise leading to Roche becoming the global leader in oncology. In 2007, he also took on the additional responsibility of Leader, Disease Biology Leadership Team, in the new R&D model of Roche.
Gary S. Firestein, M.D.
Dr. Gary S. Firestein serves as Professor of Medicine and Chief of the Division of Rheumatology, Allergy and Immunology as well as Dean of Translational Medicine at UCSD. Dr. Firestein’s research interest has focused on the pathogenesis of rheumatoid arthritis and mechanisms of inflammation. He was among the first to map the synovial cytokine profile of RA and demonstrate the dominance of macrophage and fibroblast products. These studies contributed to the development of the highly effective anti-TNF approaches to RA. His laboratory has also worked extensively on signal transduction pathways as potential therapeutic targets. His studies identifying the key signaling molecules regulating synovial inflammation served as pivotal proof of concept studies for targets like IKKß and JNK. In addition, he has directed a number of innovative clinical studies for the treatment of rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and scleroderma, and autoinflammatory syndromes with a focus on developing novel biomarker studies. Dr. Firestein founded the UCSD Center for Innovative Therapy to promote translational research in inflammatory and autoimmune diseases and in 2003 was named the founding Director of the UCSD Clinical and Translational Research Institute (CTRI). He also served as a chairman of the FDA Arthritis Advisory Committee for two years. Dr. Firestein received his A.B. degree summa cum laude from Harvard College in 1976 and subsequently received his M.D. degree from Johns Hopkins University School of Medicine.
David Fruman, Ph.D.
Professor Fruman is Associate Professor in the Department of Molecular Biology & Biochemistry at the University of California, Irvine. He also serves as Associate Director of the Center for Immunology at UC Irvine. Trained in the fields of Immunology and Cancer Biology, Dr. Fruman's research focuses on the signal transduction pathways that drive cell division and survival in the immune system. Dr. Fruman received his Ph.D. from Harvard University.
Stephen V. Frye, Ph.D.
Dr. Frye is the Director of the Center for Integrative Chemical Biology and Drug Discovery and a Research Professor within the Medicinal Chemistry and Natural Products Division in the School of Pharmacy at the University of North Carolina at Chapel Hill. Dr. Frye was previously the Worldwide VP of Discovery Medicinal Chemistry at GlaxoSmithKline where he directed all hit to lead discovery activities for the company. While at GSK, Dr. Frye invented Avodart, a dual 5-alpha-reductase inhibitor to treat prostatic disease and the kinase chemistry group he led discovered Tykerb, an approved therapy for breast cancer treatment. Dr. Frye has more than 50 patents and publications.
John Gribben, M.D. DSc FRCP FRCPath FMedSci
John Gribben is Professor of Experimental Cancer Medicine, Queen Mary University of London Institute of Cancer, Barts and The London School of Medicine and Dentistry. He is the Director of The Joint Office for Research and Development, Centre Lead for the Centre of Experimental Cancer Medicine at Barts, the Clinical Lead for the North East London Cancer Network and Director of Stem Cell Transplantation at St. Bartholomew’s Hospital. He graduated from University of Glasgow Medical School in 1980. He was a Leukaemia Trust Fellow at University College London and then the recipient of a Wellcome Trust Fellowship Award. In 1989 he received a Fogarty International Fellowship to continue post-doctoral training at the Dana-Farber Cancer Institute, Harvard Medical School. In 1992 he was appointed to the Faculty at Harvard Medical School, where he remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, until returning to London in October 2004. He is an internationally recognized translational cancer researcher and the author of more than 300 manuscripts and book chapters. His primary research interests include the immunotherapy of cancer (including stem-cell transplantation); the identification of tumour antigens; and treatment in leukaemia and lymphoma. He is a founding member of the CLL Research Consortium, and a member of the MRC Molecular and Cellular Medicine Board. He is an Associate Editor of Blood and in 2008 was elected a Fellow of the Academy of Medical Science.
David Pearce, M.D.
Dr. Pearce is Professor of Medicine and Cellular and Molecular Pharmacology at the University of California San Francisco, and Chief of Nephrology at San Francisco General Hospital. He is internationally known for his pioneering work on the cellular mechanisms of hormone action in the kidney. His laboratory uses cutting edge molecular biological and cellular approaches to understand how the kidney controls blood pressure and contributes to high blood pressure and metabolic disease. His clinical activities focus on patients with kidney failure and severe disturbances of blood pressure, body fluid and electrolytes.
Dr. Pearce received his AB degree from the University of California at Berkeley and his MD from the University of Chicago, Pritzker School of Medicine. He is a member of the American Heart Association Council on High Blood Pressure Research, the UCSF Institute of Molecular Medicine, as well as the California Honor Society. He is a Fellow of the American Society of Nephrology, and in 2009 he received the National Kidney Foundation “Champions of Hope Award” for his pioneering research and clinical work on behalf of patients with kidney disease.
Zachary Knight, Ph.D.
Dr. Knight, Ph.D. is currently a Life Sciences Research Foundation Fellow at Rockefeller University. Dr. Knight is a co-founder of Intellikine who received his Ph.D. from the University of California San Francisco where he discovered and developed highly selective small molecule inhibitors of the PI3K/mTOR pathway using a genome wide pharmacological approach he pioneered. Dr. Knight serves as an advisor to Intellikine in the area of PI3K family pharmacology as well as biomarker discovery and pathway analysis.
Neal Rosen, M.D., Ph.D.
Professor Rosen is a Member in the Department of Medicine and in the Program in Molecular Pharmacology and Chemistry at the Memorial Sloan-Kettering Cancer Center where he serves as the Head of Developmental Therapeutics and holds the Enid A. Haupt Chair in Medical Oncology. Dr. Rosen is also a Professor of Pharmacology, Cell Biology and Medicine at the Cornell University Medical School. His major interests are the identification and study of the key molecular events and growth signaling pathways responsible for the development of prostate, breast, melanoma and other human cancers, and the use of this information for the development of mechanism-based therapeutic strategies. Dr. Rosen received his undergraduate degree in Chemistry from Columbia College and an MD, PhD in Molecular Biology from the Albert Einstein College of Medicine.
Richard M. Soll, Ph.D.
Dr. Soll is currently Vice President, Medicinal Chemistry at WuXi PharmaTech in Shanghai, China. Previously he was the Chief Scientific Officer and Vice President, R&D at the San Diego based company TargeGen where he led innovative clinical-stage drug discovery and development programs for isoform-specific PI3K inhibitors as therapeutics for inflammation, respiratory disease and cancer, mutitargeted src/VEGF inhibitors as the first topical kinase inhibitors for age-related macular degeneration and highly selective JAK2 inhibitors for the treatment of myeloproliferative disorders. Dr. Soll was the Vice President of Chemistry at Ontogen and also founded the chemistry department at 3-Dimensional Pharmaceuticals where he ultimately served as Vice President, Chemistry. Dr. Soll's drug discovery and development experiences span numerous clinical indications and cover a wide range of molecular targets including inhibitors of kinases, serine proteases, GPCRs and protein-protein interactions. Dr. Soll has extensively published in peer reviewed journals and is an inventor of numerous issued and pending patents.
Edgar Ulm, Ph.D.
Edgar Ulm served as our Head, Development from 2007 through 2009. Prior to Intellikine, Dr. Ulm was Senior Director, Oncology Research and Development at Biogen Idec, California, Vice President, Preclinical Development at Conforma Therapeutics, California and Executive Director responsible for the drug metabolism, toxicology and clinical pharmacokinetic functions at Ligand Pharmaceuticals. His pharmaceutical research and development experience includes 17 years at Merck & Co. Dr. Ulm received his Ph.D. in biochemistry from Purdue University.
Bart Vanhaesebroeck, MSc, Ph.D.
Professor Vanhaesebroeck is currently Professor in Cell Signalling at Barts & the London Medical School, UK. Dr. Vanhaesebroeck gained a Masters degree in Biology and a Ph.D. in Molecular Biology at Ghent University, Belgium. Following postdoctoral work in Ghent, and a brief stay at the University of Padova, Italy, he started postdoctoral work at the Ludwig Institute for Cancer Research, London to work on PI 3-kinases. He subsequently became Assistant and Associate Member of the Ludwig Institute for Cancer Research, and Lecturer and Professor at the Department of Biochemistry & Molecular Biology at University College London. In 2007, Dr. Vanhaesebroeck moved to Barts and the London to establish the Centre for Cell Signaling. His research efforts focus on understanding the roles of PI 3-kinase isoforms in normal physiology and disease. He and his team have pioneered the use of mouse gene targeting, which mimics pharmacological inhibitors, allowing the validation of specific PI 3-kinase isoforms as disease targets, with work published in Science and Nature. A key success of his work was in the identification of p110 PI3K as new targets in immunity and inflammation, an achievement that has been incorporated into drug discovery efforts at Intellikine and elsewhere.